A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs ASP 3325 (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 31 Jul 2015 New trial record